THE FACT ABOUT MBL77 THAT NO ONE IS SUGGESTING

mutations provided The reality that, as spelled out below, CLL therapy relies to the presence or absence of such mutations. The current consensus is that, besides clonal mutations, subclonal mutations using a variant allelic frequency starting from five to ten% (and for that reason down below the brink of detection by standard molecular strategies)